

Codexis Pipeline Snapshot



Pipeline Project Category	Pre-Commercial		Commercial	Pipeline Total 6/30/17	<i>vs. prior pipeline</i> 6/30/16
	Codexis Driven		Sustaining Revenues		
	<i>Codexis Self-funded</i>	<i>Customer Partnered</i>	<i>Product Sales and/or Licensing</i>		
Biocatalysts to Reduce Small Molecule Drug Costs:					
<i>Developmental Drugs in Clinical Phase II or later</i>		10	n.a.	10	+3
<i>Patented On-the-Market Drugs</i>		1	2	3	-
<i>Generic On-the-Market Drugs</i>	1	3	5	9	+2
Discovery & Development of Novel Biotherapeutics	5	1		6	+2
Improving Products & Processes ex-Pharmaceuticals:					
<i>Food Ingredients</i>		3	1	4	-
<i>Molecular Biology & Diagnostics</i>	1			1	-
Pipeline Total as of June 30, 2017	7	18	8	33	+7

Guide to Codexis Pipeline Snapshot



Row Headers

- > Independent categories in which Codexis is creating protein innovations that can liberate value-in-use
- > Excludes biocatalysts for small molecule pharmaceuticals prior to and through Phase 1 development, as they are too numerous, unclear regards stage of development, and collectively of minimal revenue impact

Column Headers

- > **ALL Projects are Codexis Driven** - projects where protein innovations have been or are being developed by Codexis teams
- > **Pre-Commercial** are projects that have yet to be commercially launched by Codexis and/or our customers
- > **Commercial** projects or products that have been fully commercialized by both Codexis and our customers, and are sources of sustained revenues for Codexis
- > **Note:** We have dropped the 'CodeEvolver® Licensee Driven' column from our pipeline snapshot. There are sensitivities to their disclosures that make accurate, routine updating in our pipeline impractical

For a Project to Register in our Pipeline

- > It must have generated > \$100,000 in revenue and/or incurred > \$100,000 in costs over the prior 2 years



Appendix

Codexis Historical Pipeline Snapshots

Codexis Pipeline Snapshot – June 2016

Converted to new format



Pipeline Project Category	Pre-Commercial		Commercial	Pipeline Total 6/30/16
	Codexis Driven		Sustaining Revenues	
	<i>Codexis Self-funded</i>	<i>Customer Partnered</i>	<i>Product Sales and/or Licensing</i>	
Biocatalysts to Reduce Small Molecule Drug Costs:				
<i>Drug Candidate in Clinical Phase II or later</i>		7	n.a.	7
<i>Patented On-the-Market Drugs</i>		1	2	3
<i>Generic On-the-Market Drugs</i>		2	5	7
Discovery & Development of Novel Biotherapeutics	2	2		4
Improving Products & Processes ex-Pharmaceuticals:				
<i>Food Ingredients</i>	1	2	1	4
<i>Molecular Biology & Diagnostics</i>	1			1
Pipeline Total as of June 30, 2016	4	14	8	26